News | June 22, 2022
AstraZeneca and Merck announces results from phase 3 PROpel trial of Lynparza
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
Acceptance based on results from the phase 3 KEYNOTE-091 trial
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
The new Oncology CRO will aim to drive faster execution and higher quality trial outcomes for Oncology sponsors.
Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection
Subscribe To Our Newsletter & Stay Updated
